IDEXX Laboratories (NASDAQ:IDXX) Releases Quarterly Earnings Results, Beats Estimates By $0.55 EPS

IDEXX Laboratories (NASDAQ:IDXX) released its quarterly earnings data on Friday. The company reported $1.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.55, MarketWatch Earnings reports. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 264.71%. The firm had revenue of $637.20 million during the quarter, compared to analysts’ expectations of $589.98 million. During the same period last year, the business earned $1.43 earnings per share. IDEXX Laboratories’s revenue was up 2.8% compared to the same quarter last year.

Shares of NASDAQ IDXX opened at $397.75 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.60 and a debt-to-equity ratio of 7.06. The stock has a market capitalization of $33.78 billion, a PE ratio of 79.55, a PEG ratio of 6.12 and a beta of 0.81. IDEXX Laboratories has a twelve month low of $168.65 and a twelve month high of $407.86. The stock has a fifty day simple moving average of $335.38 and a 200-day simple moving average of $286.60.

In other news, Director Jonathan W. Ayers sold 13,600 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $286.07, for a total value of $3,890,552.00. Following the completion of the transaction, the director now owns 810,467 shares of the company’s stock, valued at $231,850,294.69. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Giovani Twigge sold 14,070 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $307.73, for a total transaction of $4,329,761.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,182 shares of company stock worth $31,409,008. 2.53% of the stock is owned by corporate insiders.

Several analysts have recently weighed in on IDXX shares. TheStreet raised shares of IDEXX Laboratories from a “c+” rating to a “b-” rating in a research note on Thursday, April 30th. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $280.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Bank of America increased their price target on IDEXX Laboratories from $300.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. IDEXX Laboratories has a consensus rating of “Buy” and an average target price of $317.14.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Hold Rating

Earnings History for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.